JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

Search

Eli Lilly and Co.

Gesloten

SectorGezondheidszorg

757.36 3.2

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

753.34

Max

757.36

Belangrijke statistieken

By Trading Economics

Inkomsten

-6.1B

2.8B

Verkoop

-804M

13B

K/W

Sectorgemiddelde

61.579

56.602

EPS

3.34

Dividendrendement

0.82

Winstmarge

21.678

Werknemers

47,000

EBITDA

-2B

4.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+30.59% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.82%

2.45%

Volgende Winsten

6 aug 2025

Volgende dividenddatum

10 jun 2025

Volgende Ex Dividend datum

14 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-149B

678B

Vorige openingsprijs

754.16

Vorige sluitingsprijs

757.36

Nieuwssentiment

By Acuity

26%

74%

53 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Eli Lilly and Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 mei 2025, 11:24 UTC

Winsten

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

22 apr 2025, 09:26 UTC

Belangrijke Marktbewegers

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

18 apr 2025, 15:57 UTC

Belangrijke Marktbewegers

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

12 mei 2025, 22:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mei 2025, 18:45 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mei 2025, 17:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 mei 2025, 17:01 UTC

Top Nieuws

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mei 2025, 13:56 UTC

Winsten

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mei 2025, 11:18 UTC

Winsten

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mei 2025, 09:30 UTC

Top Nieuws

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 mei 2025, 20:30 UTC

Top Nieuws

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 mei 2025, 04:05 UTC

Acquisities, Fusies, Overnames

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 mei 2025, 21:07 UTC

Marktinformatie

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 mei 2025, 14:07 UTC

Winsten

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mei 2025, 12:47 UTC

Winsten

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

1 mei 2025, 12:00 UTC

Top Nieuws

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

1 mei 2025, 11:58 UTC

Winsten

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mei 2025, 11:06 UTC

Winsten

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mei 2025, 10:48 UTC

Winsten

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

1 mei 2025, 10:48 UTC

Winsten

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

1 mei 2025, 10:45 UTC

Winsten

Eli Lilly 1Q Adj EPS $3.34 >LLY

1 mei 2025, 10:45 UTC

Winsten

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

1 mei 2025, 10:45 UTC

Winsten

Eli Lilly 1Q Net $2.76B >LLY

1 mei 2025, 10:45 UTC

Winsten

Eli Lilly 1Q Rev $12.73B >LLY

1 mei 2025, 10:45 UTC

Winsten

Eli Lilly 1Q EPS $3.06 >LLY

1 mei 2025, 10:45 UTC

Winsten

Eli Lilly Sees FY Adj EPS $20.78-Adj EPS $22.28 >LLY

30 apr 2025, 09:30 UTC

Top Nieuws

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

28 apr 2025, 13:58 UTC

Top Nieuws

IBM, Apple, Eli Lilly: Tracking Corporate Spending Pledges Under Trump -- WSJ

22 apr 2025, 09:31 UTC

Populaire aandelen

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

17 apr 2025, 18:27 UTC

Top Nieuws

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

Peer Vergelijking

Prijswijziging

Eli Lilly and Co. Prognose

Koersdoel

By TipRanks

30.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 989.07 USD  30.59%

Hoogste 1,124 USD

Laagste 700 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Eli Lilly and Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

17

Buy

1

Hold

1

Sell

Technische score

By Trading Central

N/A / 884.54Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

53 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.